Table 1.
Development of symptomatology during CBD treatment
| T1 (baseline) | T2 (4 week follow-up) | T3 (8 week follow-up) | |
|---|---|---|---|
| Before CBD onset | After stopping sertraline | Stable CBD treatmenta | |
| Depressive Symptoms | |||
| Raw scores (cut-off label) of the BDI-IIb |
22 (Moderate depressive episode) |
10 (Minimal depressive episode) |
7 (Minimal depressive episode) |
| Anxiety Symptoms | |||
| Raw scores (T values) of the German FSSC‑Rb | 52 (60) | – | 31 (50) |
| Fear of Danger and Deathb | 7 (50) | – | 4 (45) |
| Fear of Separation | 5 (45) | – | 4 (45) |
| Social Anxietyb | 13 (70) | – | 7 (60) |
| Fear of the Unknownb | 13 (70) | – | 9 (60) |
| Fear of Animals | 2 (50) | – | 3 (55) |
| Medical Fearsb | 7 (65) | – | 3 (50) |
| Fear of Evaluation and School Anxietyb | 5 (55) | – | 1 (45) |
| At-risk mental state | |||
| Raw scores of the ERIraosb | 12 | – | 4 |
| Mental disorder b (affective symptoms, withdrawal, school and sleep problems) | 4 | – | 0 |
| At-risk psychosis b (rumination, social insecurity, paranoia, special interests, tension) | 5 | – | 2 |
| Beginning psychosis (depersonalisation, derealisation, symptoms of schizophrenia) | 3 | – | 2 |
aStable medication with CBD, no other psychopharmacological treatment applied
bShow clinically relevant improvement